Treatment of bladder cancer cells in vitro and in vivo with 2-5A antisense telomerase RNA

Gene Therapy
S KogaS Kondo

Abstract

Bladder cancer is the most common malignant tumor of the urinary tract. Novel treatment approaches are essential because of the failure of current treatment options to cure a high percentage of patients. Telomerase, a ribonucleoprotein, is detected in almost all bladder cancer, but not in normal bladder tissues. Therefore, telomerase is expected to be a very promising candidate for targeted therapy of bladder cancer. In this study, we synthesized a 19-mer antisense oligonucleotide against the RNA component of human telomerase (hTR) linked to a 2-5A molecule (2-5A-anti-hTR) and investigated its antitumor effect against bladder cancer cells. The 2-5A antisense strategy relies on the recruitment and activation of RNase L at the site of targeted RNA sequence. Here we demonstrate that treatment with 2-5A-anti-hTR reduced the viability of seven bladder cancer cell lines (UM-UC-2, UM-UC-3, UM-UC-6, UM-UC-9, UM-UC-14, RT4 and T24) expressing telomerase activity to 21-55% within 4 days. The cytotoxicity was mainly due to induction of caspase-dependent apoptosis. In contrast, normal fibroblast WI38 cells lacking telomerase activity were resistant to the treatment. Furthermore, treatment of subcutaneous UM-UC-2 tumors in nude mice with 2-...Continue Reading

References

Feb 1, 1970·The Journal of Urology·D C UtzG M Farrow
Feb 1, 1982·The Journal of Urology·W LutzeyerH Dahm
Sep 1, 1995·Science·J FengJ Yu
Jan 1, 1994·Cold Spring Harbor Symposia on Quantitative Biology·C B HarleyC W Greider
Apr 1, 1995·Current Opinion in Genetics & Development·C B Harley, B Villeponteau
Feb 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·P F TorrenceR H Silverman
Aug 14, 1996·Biochemical and Biophysical Research Communications·Y KanazawaN Hayashi
Jan 1, 1996·Current Opinion in Oncology·J W Shay, W E Wright
Feb 14, 1997·Science·L HarringtonM O Robinson
Mar 4, 1997·Proceedings of the National Academy of Sciences of the United States of America·N M CirinoR H Silverman
Feb 5, 1998·CA: a Cancer Journal for Clinicians·S H LandisP A Wingo
May 1, 1996·Nature Biotechnology·J C NortonD R Corey
Jul 10, 1998·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·S KondoB P Barna
Jul 24, 1998·Biochemical and Biophysical Research Communications·A I GlukhovS E Severin
Mar 31, 1999·Proceedings of the National Academy of Sciences of the United States of America·A J Lustig
Aug 10, 1999·Nature·W C HahnR A Weinberg
Sep 29, 1999·Genes & Development·X ZhangM O Robinson
Sep 30, 1999·Nature Medicine·W C HahnR A Weinberg

❮ Previous
Next ❯

Citations

Nov 13, 2008·Cytotechnology·Lionel GuittatJean-Louis Mergny
Jan 31, 2006·Molecular and Cellular Biochemistry·A ShervingtonL Shervington
Jun 14, 2003·Pharmacology & Therapeutics·Kathleen F PirolloEsther H Chang
May 22, 2003·Cancer Letters·Gabriele Saretzki
Aug 15, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·N ZaffaroniM G Daidone
Jul 10, 2003·Critical Reviews in Oncology/hematology·Richard J Cote, Ram H Datar
Jul 20, 2002·Current Opinion in Pharmacology·Evonne M RezlerLaurence H Hurley
Apr 25, 2000·Annual Review of Medicine·V UrquidiS Goodison
Jan 24, 2003·Annual Review of Pharmacology and Toxicology·Evonne M RezlerLaurence H Hurley
Oct 23, 2008·Journal of Cancer Research and Clinical Oncology·Christian BolenzMaurice Stephan Michel
Feb 16, 2005·Expert Opinion on Biological Therapy·Anthony J GlackinKate E Williamson
Jan 5, 2002·Expert Opinion on Investigational Drugs·P J PerryT C Jenkins
Apr 26, 2006·Expert Opinion on Investigational Drugs·Hideaki MiyakeMartin E Gleave
Sep 8, 2007·Biochimie·Anne De CianJean-Louis Mergny
Jul 3, 2007·British Journal of Pharmacology·P Phatak, A M Burger
Aug 29, 2006·European Urology·Susanne FuesselManfred P Wirth
Feb 14, 2006·Critical Reviews in Oncology/hematology·Ken André OlaussenJean-Charles Soria
Jun 9, 2009·Bioorganic & Medicinal Chemistry Letters·Bhahwal Ali ShahSubhash Chandra Taneja
Mar 15, 2006·American Journal of Surgery·Sergio HuertaEdward H Livingston
Dec 13, 2005·Expert Review of Anticancer Therapy·Hideaki MiyakeMartin E Gleave
Nov 25, 2003·Oncogene·Bryan C BarnhartMarcus E Peter
Feb 19, 2002·Oncogene·Tadashi KomataSeiji Kondo
Jan 8, 2009·The Korean journal of laboratory medicine·Yuk Pheel ParkHee Gu Lee
Sep 13, 2003·World Journal of Gastroenterology : WJG·Qing-You DuSheng-Qi Wang
Jan 22, 2003·Journal of the American Geriatrics Society·Ali Ahmed, Trygve Tollefsbol

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.